Watch: Correlation Between Patient and Physicians Assessments in PsA Save Dr. Antoni Chan interviews Dr. Avin Maroof at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23 https://t.co/syG4Ry08vF https://t.co/6g9SpISSIt

Merging field moving forward - cardio-rheumatology collaboration imp! Calcium scores in older patients with #RA may be the one take away! Very important to risk predict and mitigate CV events . Ofcourse history taking still remains key! session 14T118 #ACR23 @RheumNow https://t.co/xoldFlA8EW

#ACR23 Late-Breaking Abstr#L13 CAR-T is in CT but not RCT yet. Preliminary results from open label (N=3 #SLE of YTB323 (rapcabtagene autocel CD19 directed with preserved T cell stemness) showed favourable CAR T expansion, B cell depletion, early efficacy & safety @RheumNow https://t.co/UQUOfDbFJe

A#2316 #ACR23 @RheumNow 91 SLE pts w COVID v 182 SLE wo COVID ifn 11 SLE/COVID: serious disease 1 death, 7 severe compl W/in 90d, 15% mild/mod SLE flare 2% severe SLE flare Flare rate 17.6% higher than no COVID ifn 5% p=0.001 High HV ifn (2% v 1%) dsDNA/C3 changes not signif diff https://t.co/dxGJNNWuFy

How do we treat #VEXAS - UBA1 mutation Large multicenter cohort - 110 pts, 99% M Confirms the benefit of JAKi and tocilizumab Others not so much @RheumNow #ACR23 #ACRBest #abstL03 https://t.co/tRjO31IHiD

Speaking of real RA drugs for RA-ILD... large multicenter study finds 4 in 5 patients who received ABA had lung stabilization Nice to see observational data; this would be an amazing opportunity for a pragmatic open label RCT @RheumNow #ACR23 Abstr 2165 https://t.co/LTpfjTVAur

Retrospective database study from Japan of PsA pts: At 12/24 mos ffg tx initiation, 37.5%/49% of pts discontinued index bDMARD while 22.2%/31.2% switched tx. Dc rates lowest for risankizumab 🤔Reasons for switching/discontinuation not mentioned. #ACR23 ABST2246 @RheumNow https://t.co/6dhKZmp1wE

A#2313 #ACR23 @RheumNow Utilization of inpt palliative care incr from 2016-2020 in SLE admits from 1.8% 2016 to 2.6% 2020 Pall care use incr: older pt, comorbid index, teaching, large hosps Lower use: age <35 yo, Black & Hispanic race Need to address racial disparities in utiliz https://t.co/wQ8NOhm9lK https://t.co/3tJgt4MMDf

Important data re:ADVOCATE study and health related quality of life Interesting question: is this due to AVA or just simply giving less steroids? I discuss this on recent podcast: https://t.co/7Jm6ArFpsB @RheumNow #ACR23 https://t.co/53T1p2Vvyb

@EricFMorand SPOCS Study: A#2263 @ACR23 826 pts - 71% high IFN gene sig Mean SLEDAI-2K lower with low IFNGS 6mo: pts reports 1+ flare 19% high IFNGS, 16% low. Both grps 6.7% LLDAS, but remission 4% low/1.7% high In 36 mo, <10% LLDAS, <10% remission @earlyARA @RheumNow https://t.co/z5v4TBVuDG

Post hoc analysis of Ph2 AURA-LV & Ph3 AURORA1 ⬆️VOC-treated pts achieved CRR at 1yr vs. control arm (41.0% vs. 21.9%; OR 2.48, p< 0.0001) and PRR at 1yr (OR 2.3, p< 0.0001) Similar safety profiles VOC: Additional tx option for LN pts w/ UPCR >/=2g/g #ACR23 ABST2326 @RheumNow https://t.co/9z1n3s7umU